Financial reports
10-K
2023 FY
Annual report
25 Mar 24
10-K/A
2022 FY
Annual report (amended)
25 Mar 24
10-Q
2023 Q3
Quarterly report
9 Nov 23
10-Q
2023 Q2
Quarterly report
11 Aug 23
10-Q
2023 Q1
Quarterly report
15 May 23
10-K
2022 FY
Annual report
28 Mar 23
10-Q
2022 Q3
Quarterly report
18 Nov 22
Current reports
8-K
Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review
25 Mar 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
1 Feb 24
8-K
Submission of Matters to a Vote of Security Holders
22 Dec 23
8-K
Regulation FD Disclosure
5 Dec 23
8-K
Coeptis Therapeutics Announces $2 Million Private Placement
27 Oct 23
8-K
Unregistered Sales of Equity Securities
12 Oct 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
30 Aug 23
8-K
Coeptis Therapeutics Completes Exclusive License for Allogeneic Immuno-Oncology Platform and Clinical Stage Assets from Deverra Therapeutics
22 Aug 23
8-K
Coeptis Therapeutics Holdings, Inc. Announces Pricing of $3.5 Million
16 Jun 23
8-K
Coeptis Therapeutics Receives Approval to Transfer to The Nasdaq Capital Market
9 Jun 23
Registration and prospectus
424B3
Prospectus supplement
26 Mar 24
424B3
Prospectus supplement
26 Mar 24
424B3
Prospectus supplement
5 Feb 24
424B3
Prospectus supplement
5 Feb 24
424B3
Prospectus supplement
15 Dec 23
424B3
Prospectus supplement
30 Nov 23
S-1
IPO registration
15 Nov 23
D
$2.00 mm in equity, sold $2.00 mm, 1 investor
3 Nov 23
424B3
Prospectus supplement
26 Sep 23
424B4
Prospectus supplement with pricing info
15 Jun 23
Proxies
DEF 14A
Definitive proxy
17 Nov 23
PRE 14A
Preliminary proxy
7 Nov 23
DEF 14A
Definitive proxy
11 Oct 22
PRE 14A
Preliminary proxy
30 Sep 22
DEFA14A
Additional proxy soliciting materials
19 Apr 22
DEFA14A
Additional proxy soliciting materials
19 Apr 22
DEF 14A
Definitive proxy
5 Apr 22
PRE 14A
Preliminary proxy
18 Mar 22
DEF 14A
Definitive proxy
19 Nov 21
Other
EFFECT
Notice of effectiveness
30 Nov 23
CORRESP
Correspondence with SEC
28 Nov 23
UPLOAD
Letter from SEC
22 Nov 23
EFFECT
Notice of effectiveness
14 Jun 23
CORRESP
Correspondence with SEC
12 Jun 23
CORRESP
Correspondence with SEC
12 Jun 23
UPLOAD
Letter from SEC
23 Feb 23
EFFECT
Notice of effectiveness
3 Oct 22
CORRESP
Correspondence with SEC
29 Sep 22
CORRESP
Correspondence with SEC
26 Sep 22